CSF, blood-brain barrier, and brain drug delivery

Expert Opinion on Drug Delivery

Volumn 13, Issue 7, 2016, Pages 963-975

  Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; brain drug delivery; cerebrospinal fluid; choroid plexus; diffusion; microvasculature

Indexed keywords

ATENOLOL; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLECYSTOKININ; CORTICOSTEROID; GLUCOSE TRANSPORTER 1; INTERFERON; NERVE GROWTH FACTOR; PARACETAMOL; PLASMA PROTEIN; SOMATOMEDIN C; SUCROSE; TRANSFERRIN; ZIDOVUDINE;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN HOMOGENATE; BRAIN SIZE; CEREBROSPINAL FLUID; CHOROID PLEXUS; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TRANSPORT; ELECTRIC RESISTANCE; HUMAN; NONHUMAN; NUTRIENT; REVIEW; SANFILIPPO SYNDROME; SURFACE AREA; THERAPEUTIC MISCONCEPTION; THERMODYNAMICS; ANIMAL; BRAIN; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CHOROID PLEXUS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84962853255     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1171315     Document Type: Review

References (89)

1. H.Duvernoy, S.Delon, J.L.Vannson The vascularization of the human cerebellar cortex. Brain Res Bull. 1983 Oct;11:419–480.• Impressive collection of scanning electron micrographs of the human brain microvasculature.
2. M.Verrees, W.R.Selman. Management of normal pressure hydrocephalus. Am Fam Physician. 2004;70:1071–1078.
3. H.Davson. Review lecture. The blood-brain barrier. J Physiol. 1976 Feb;255:1–28.
4. N.R.Saunders, -J.-J.Dreifuss, K.M.Dziegielewska, et al. The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history. Front Neurosci. 2014;8:404.
5. E.E.Goldmann. The process of digestion: illustrated by the action of stains on the living tissues. The Lancet. 1913;185:69–71.
6. F.W.Mott, The late Professor Edwin Goldmann’s investigations on the central nervous system by vital staining. Brit Med J. 1913;2:871–873.•• Mott reviews the classic experiments of Goldmann on acidic vital dyes and is essential reading for the historical origins of the BBB and the misconceptions with regard to choroid plexus and CSF.
7. J.McIntosh, P.Fildes, The factors which govern the penetration of arsenic (salvarsan) and aniline dyes into the brain and their bearin upon the treatment of cerebral syphilis. Brain. 1916;39:478–483.•• Early observation that basic vital dyes pass directly from blood to brain without traversing an intermediate CSF compartment.
8. T.Broman. The possibilities of the passage of substances from the blood to the central nervous system. Acta Psych Et Neurol. 1941;16:1–25.
9. U.Friedemann. Blood-brain barrier. Physiol Rev. 1942;22:125–142.
10. L.P.Rowland. Blood-brain barrier, cerebrospinal fluid, brain edema, and hydrocephalus. In: E.R.Kandel, J.H.Schwartz, editors. Principles of neural science. New York: Elsevier; 1985. p. 837–844.
11. P.Ehrlich. Address in pathology, on chemiotherapy: delivered before the seventeenth international congress of medicine. Br Med J. 1913 [Aug16];2:353–359.• Reviews the development of a model chemotherapeutic, salvarsan, an organoarsenical compound. The drug was marketed by Hoechst for 30 years for the treatment of syphilis.
12. J.McIntosh, P.Fildes, The fixation of arsenic by the brain after intravenous injections of salvarsan. Proc R Soc Lond B. 1914;88:320–326.• Demonstration that salvarsan does not cross the BBB and not effective in the treatment of neurosyphilis. This was the first indication that the BBB would be a problem in the development of chemotherapeutics for the brain.
13. H.Davson, K.Welch, M.B.Segal. The physiology and pathophysiology of the cerebrospinal fluid. London: Churchill Livingstone; 1987.
14. D.G.Poplack, W.A.Bleyer, J.H.Wood, et al. A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res. 1977 Jul;37:1982–1985.
15. C.L.Farrell, W.M.Pardridge. Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc Natl Acad Sci U S A. 1991 [Jul1];88:5779–5783.
16. W.M.Pardridge, R.J.Boado, C.R.Farrell. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J Biol Chem. 1990 [Oct15];265:18035–18040.
17. C.L.Farrell, J.Yang, W.M.Pardridge. GLUT-1 glucose transporter is present within apical and basolateral membranes of brain epithelial interfaces and in microvascular endothelia with and without tight junctions. J Histochem Cytochem. 1992 Feb;40:193–199.
18. F.Lauwers, F.Cassot, V.Lauwers-Cances, et al. Morphometry of the human cerebral cortex microcirculation: general characteristics and space-related profiles. NeuroImage. 2008;39:936–948.• Detailed morphometric analysis of the human brain microvasculature.
19. G.J.Dohrmann. The choroid plexus: a historical review. Brain Res. 1970 [Mar3];18:197–218.
20. R.F.Keep, H.C.Jones. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Brain Res Dev Brain Res. 1990 [Oct1];56:47–53.• The first quantitative study on the surface area of the choroid plexus in the rat.
21. E.M.Cornford, J.B.Varesi, S.Hyman, et al. Mitochondrial content of choroid plexus epithelium. Exp Brain Res. 1997 Oct;116:399–405.
22. R.Spector, R.F.Keep, S.Robert Snodgrass, et al. A balanced view of choroid plexus structure and function: focus on adult humans. Exp Neurol. 2015 May;267:78–86.
23. C.Crone. The permeability of capillaries in various organs as determined by the use of the ‘indicator diffusion’ method. Acta Physiol Scand. 1963;58:292–305.
24. W.M.Pardridge, D.Triguero, J.Yang, et al. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther. 1990;253:884–891.
25. W.M.Pardridge, J.D.Connor, I.L.Crawford. Permeability changes in the blood-brain barrier: causes and consequences. CRC Crit Rev Toxicol. 1975;3:159–199.
26. M.W.Brightman, J.H.Tao-Cheng. Tight junctions of brain endothelium and epithelium. In: W.M.Pardridge, editor. The blood-brain barrier. New York: Raven; 1993. p. 107–125.
27. J.M.Anderson. Molecular structure of tight junctions and their role in epithelial transport. News Physiol Sci. 2001;16:126–130.
28. T.W.Bouldin, M.R.Krigman. Differential permeability of cerebral capillary and choroid plexus to lanthanum ion. Brain Res. 1975;99:444–448.
29. T.Zeuthen, E.M.Wright. Epithelial potassium transport: tracer and electrophysiological studies in choroid plexus. J Membr Biol. 1981;60:105–128.
30. A.M.Butt, H.C.Jones, N.J.Abbott. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol. 1990 Oct;429:47–62.
31. Q.R.Smith, S.I.Rapoport. Cerebrovascular permeability coefficients to sodium, potassium, and chloride. J Neurochem. 1986 Jun;46:1732–1742.
32. C.Crone. The permeability of brain capillaries to non-electrolytes. Acta Physiol Scand. 1965;64:407–417.
33. R.K.Ferguson, D.M.Woodbury. Penetration of 14C-inulin and 14C-sucrose into brain, cerebrospinal fluid, and skeletal muscle of developing rats. Exp Brain Res. 1969;7:181–194.
34. A.Nadal, E.Fuentes, J.Pastor, et al. Plasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes. Proc Natl Acad Sci U S A. 1995 [Feb28];92:1426–1430.
35. R.J.Boado, Y.Zhang, Y.Zhang, et al. Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem. 2007 Mar-Apr;18:447–455.
36. H.Reiber, Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci. 2003;21:79–96.• Shows that all plasma proteins are freely transported into CSF at a rate inversely related to molecular weight.
37. B.Bohrmann, K.Baumann, J.Benz, et al. Gantenerumab: a novel human anti-abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28:49–69.• Recites the classic misconception that therapeutic antibodies have some basal BBB transport, because the CSF/plasma ratio of IgG is 0.1–0.2%.
38. A.Kaddoumi, S.-U.Choi, L.Kinman, et al. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos. 2007;35:1459–1462.
39. R.Yarchoan, S.Broder. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med. 1987 [Feb26];316:557–564.
40. A.E.Ahmed, S.Jacob, J.P.Loh, et al. Comparative disposition and whole-body autoradiographic distribution of [2-14C]azidothymidine and [2-14C]thymidine in mice. J Pharmacol Exp Ther. 1991 Apr;257:479–486.
41. U.Bickel. How to measure drug transport across the blood-brain barrier. NeuroRx. 2005;2:15–26.
42. T.Terasaki, S.Ohtsuki. Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology. NeuroRx. 2005;2:63–72.
43. W.M.Pardridge, E.M.Landaw. Testosterone transport in brain: primary role of plasma protein-bound hormone. Am J Physiol. 1985 Nov;249:E534–42.
44. C.L.Shaffer. Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross species pharmacologic exposure-response relationships. Ann Rep Med Chem. 2010;45:55–70.
45. M.Friden, F.Bergstrom, H.Wan, et al. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Met Dispos. 2011;39:353–362.
46. I.Westergren, B.Nystrom, A.Hamberger, et al. Intracerebral dialysis and the blood-brain barrier. J Neurochem. 1995 Jan;64:229–234.
47. D.R.Groothuis, S.Ward, K.E.Schlageter, et al. Changes in blood-brain barrier permeability associated with insertion of brain cannulas and microdialysis probes. Brain Res. 1998 [Aug24];803:218–230.
48. M.M.Morgan, D.Singhal, B.D.Anderson. Quantitative assessment of blood-brain barrier damage during microdialysis. J Pharmacol Exp Ther. 1996;277:1167–1176.
49. D.J.Reed, D.M.Woodbury. Kinetics of movement of iodide, sucrose, inulin and radio-iodinated serum albumin in the central nervous system and cerebrospinal fluid of the rat. J Physiol. 1963 Dec;169:816–850.
50. R.A.Fishman, N.P.Christy. Fate of adrenal cortical steroids following intrathecal injection. Neurology. 1965 Jan;15:1–6.• Early work showing that injection of drug into CSF is equivalent to a slow intravenous injection.
51. R.B.Aird. A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp Neurol. 1984 Nov;86:342–358.• Over 30 years ago, Aird reviewed the futility of intrathecal drug delivery for treatment of brain disease, apart from meningeal disease on the surface of the brain.
52. A.Billiau, H.Heremans, D.Ververken, et al. Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice. Arch Virol. 1981;68:19–25.
53. N.H.Greig, W.R.Fredericks, H.W.Holloway, et al. Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat. J Pharmacol Exp Ther. 1988 May;245:581–586.
54. J.N.Crawley, S.M.Fiske, C.Durieux, et al. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. J Pharmacol Exp Ther. 1991 Jun;257:1076–1080.
55. E.C.De Lange, M.Danhof, A.G.De Boer, et al. Critical factors of intracerebral microdialysis as a technique to determine the pharmacokinetics of drugs in rat brain. Brain Res. 1994 [Dec12];666:1–8.
56. T.N.Nagaraja, P.Patel, M.Gorski, et al. In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain. Cerebrospinal Fluid Res. 2005 [Jul26];2:5.
57. P.Calias, M.Papisov, J.Pan, et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One. 2012;7:e30341.
58. S.-H.Kan, M.Aoyagi-Scharber, S.Q.Le, et al. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. Proc Natl Acad Sci U S A. 2014 [Oct14];111:14870–14875.
59. W.M.Pardridge. Peptide drug delivery to the brain. New York: Raven; 1991.
60. D.G.Covell, P.K.Narang, D.G.Poplack. Kinetic model for disposition of 6-mercaptopurine in monkey plasma and cerebrospinal fluid. Am J Physiol. 1985 Feb;248:R147–56.
61. M.W.Brightman, T.S.Reese. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 1969 Mar;40:648–677.
62. V.A.Levin, J.D.Fenstermacher, C.S.Patlak. Sucrose and inulin space measurements of cerebral cortex in four mammalian species. Am J Physiol. 1970 Nov;219:1528–1533.
63. R.G.Blasberg, C.Patlak, J.D.Fenstermacher. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther. 1975 Oct;195:73–83.•• First quantitative study on the logarithmic decrease in drug concentrations in the primate brain following drug injection into CSF.
64. Q.Yan, C.Matheson, J.Sun, et al. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp Neurol. 1994 May;127:23–36.•• Autoradiography of brain after CSF injection of radiolabeled drug illustrates the steep logarithmic decrease in drug distribution into brain from the CSF surface.
65. D.R.Groothuis, S.Ward, A.C.Itskovich, et al. Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg. 1999 Feb;90:321–331.
66. S.M.Larson, J.A.Carrasquillo, N.-K.V.Cheung, et al. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347–360.
67. Michigan State University Brain Biodiversity Bank Human Brain Atlas. [cited 2016 Jan 6]. Available from: https://www.msu.edu/user/brains/brains/human/coronal/1840_cell.html
68. Comparative Mammalian Brain Collections. [cited 2016 Jan 6]. Available from: http://www.brainmuseum.org/
69. J.Defelipe. The evolution of the brain, the human nature of cortical circuits, and intellectual creativity. Front Neuroanat. 2011;5:29.
70. K.H.Dykstra, A.Arya, D.M.Arriola, et al. Microdialysis study of zidovudine (AZT) transport in rat brain. J Pharmacol Exp Ther. 1993 Dec;267:1227–1236.
71. P.F.Morrison, D.W.Laske, H.Bobo, et al. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol. 1994 Jan;266:R292–305.
72. C.E.Krewson, M.L.Klarman, W.M.Saltzman. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res. 1995;680:196–206.
73. M.Mak, L.Fung, J.F.Strasser, et al. Distribution of drugs following controlled delivery to the brain interstitium. J Neurooncol. 1995 Nov;26:91–102.
74. R.J.Ziegler, E.A.Salegio, J.C.Dodge, et al. Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion. Exp Neurol. 2011 Oct;231:261–271.
75. K.Yamada, A.Kinoshita, E.Kohmura, et al. Basic fibroblast growth factor prevents thalamic degeneration after cortical infarction. J Cereb Blood Flow Metab. 1991 May;11:472–478.
76. P.A.Day-Lollini, G.R.Stewart, M.J.Taylor, et al. Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp Neurol. 1997 May;145:24–37.
77. H.J.Wagner, C.Pilgrim, J.Brandl. Penetration and removal of horseradish peroxidase injected into the cerebrospinal fluid: role of cerebral perivascular spaces, endothelium and microglia. Acta Neuropath. 1974;27:299–315.
78. M.L.Rennels, T.F.Gregory, O.R.Blaumanis, et al. Evidence for a ‘paravascular’ fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res. 1985 [Feb4];326:47–63.
79. J.J.Iliff, M.Wang, Y.Liao, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012 [Aug15];4:147ra11.
80. H.F.Cserr, D.N.Cooper, P.K.Suri, et al. Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am J Physiol. 1981 Apr;240:F319–28.
81. A.Chodobski, J.Szmydynger-Chodobska, C.E.Johanson. Vasopressin mediates the inhibitory effect of central angiotensin II on cerebrospinal fluid formation. Eur J Pharmacol. 1998 [Apr24];347:205–209.
82. K.Fukuhara, T.Katafuchi, M.Yoshimura. Effects of baclofen on mechanical noxious and innocuous transmission in the spinal dorsal horn of the adult rat: in vivo patch-clamp analysis. Eur J Neurosci. 2013;38:3398–3407.
83. 2+ channels contribute to the generation of after-discharges in the spinal ventral root after cessation of noxious mechanical stimulation. J Pharmacol Sci. 2012;119:82–90.
84. X.Zhang, L.Bao, U.Arvidsson, et al. Localization and regulation of the delta-opioid receptor in dorsal root ganglia and spinal cord of the rat and monkey: evidence for association with the membrane of large dense-core vesicles. Neurosci. 1998;4:1225–1242.
85. A.K.Ommaya. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet. 1963 [Nov9];2(7315):983–984.
86. W.M.Pardridge. Targeted delivery of protein and gene medicines through the blood-brain barrier. Clin Pharmacol Ther. 2015 Apr;97:347–361.
87. C.A.Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44:235–249.
88. M.N.Pangalos, L.E.Schechter, O.Hurko. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov. 2007 Jul;6:521–532.
89. W.M.Pardridge. Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. Expert Opin Ther Targets. 2015;19:1059–1072.